Stocks Health care MIST
NASDAQ · Health careMilestone Pharmaceuticals Inc. (MIST)
It posted a net loss of $84M. In fiscal 2025 capital spending exceeded operating cash flow by $49.3M. At June 30, 2026 it held $169.7M in cash against $59.2M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Milestone Pharmaceuticals Inc.
- Net worth
- Milestone Pharmaceuticals Inc. has a market value (market cap) of $85.7M at the latest share price, and shareholders' equity of $18.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $49M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Milestone Pharmaceuticals Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Milestone Pharmaceuticals Inc. does
Milestone Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MIST.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$63.1M | -$0.75 | -$49.3M |
| 2024 | n/a | -$41.5M | -$0.67 | -$28.9M |
| 2023 | n/a | -$59.7M | -$1.39 | -$46.5M |
| 2022 | n/a | -$58.4M | -$1.38 | -$52.7M |
| 2021 | n/a | -$42.9M | -$1.02 | n/a |
| 2020 | n/a | -$50M | -$1.70 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Milestone Pharmaceuticals Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 28, 2026
- September 3, 2026Other event 8-K
- August 12, 2026
- August 12, 2026
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- June 15, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 13, 2026
- May 13, 2026Passive stake changed SCHEDULE 13G/A
- May 13, 2026
Insider trades
What the people running Milestone Pharmaceuticals Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| April 16, 2026 | Oliveto JosephPresident and CEO, Director | Soldpre-planned (10b5-1) | 36,500 | $82.5K |
| January 26, 2026 | Oliveto JosephPresident and CEO, Director | Exercised options | 66,600 | - |
| January 26, 2026 | Oliveto JosephPresident and CEO, Director | Sold | 34,523 | $66.6K |
| January 26, 2026 | Muller LorenzChief Commercial Officer | Exercised options | 20,100 | - |
| January 26, 2026 | Muller LorenzChief Commercial Officer | Sold | 11,180 | $21.6K |
| January 26, 2026 | Hasija AmitCFO & EVP of Corp. Development | Exercised options | 20,100 | - |
| January 26, 2026 | Hasija AmitCFO & EVP of Corp. Development | Sold | 12,245 | $23.6K |
| January 26, 2026 | Bharucha DavidChief Medical Officer | Exercised options | 20,100 | - |
Who owns MIST
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Propel Bio Management, LLC13G, passive with 3 related filers | 9.9% | December 23, 2025 |
| RTW Investments, LP13G, passive with 1 related filers | 9.9% | May 15, 2026 |
| Pavaki Capital Management LLC13G, passive with 2 related filers | 7.3% | August 7, 2026 |
| Adage Capital Management, L.P.13G, passive with 2 related filers | 6.37% | May 13, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 78 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Pavaki Capital Management LLC | 9,067,848 | +5,000 |
| Rtw Investments, LP | 7,833,336 | +1,502,335 |
| Propel Bio Management, LLC | 7,429,590 | +3,311,269 |
| Point72 Asset Management, L.P. | 5,411,138 | +4,325,455 |
| Simplify Asset Management Inc. | 3,349,379 | +1,842,974 |
| Millennium Management LLC | 3,142,219 | +1,597,894 |
| Kalehua Capital Management LLC | 2,538,474 | new |
| Two Sigma Investments, LP | 2,040,015 | -277,161 |
| Marshall Wace, Llp | 1,797,695 | -146,835 |
| Lion Point Capital, LP | 820,000 | 0 |
| Toronto Dominion Bank | 750,000 | 0 |
| Ameriprise Financial Inc | 666,666 | 0 |
| Boxer Capital Management, LLC | 666,666 | 0 |
| Morgan Stanley | 635,211 | -88,930 |
| UBS Group AG | 465,403 | -29,505 |
| Boothbay Fund Management, LLC | 462,669 | +293,994 |
| Susquehanna International Group, Llp | 359,895 | -159,151 |
| Aptus Capital Advisors, LLC | 339,450 | +59,200 |
| Guardian Wealth Advisors, LLC / NC | 339,450 | +59,200 |
| Seven Fleet Capital Management LP | 270,233 | -63,100 |
Insiders
5 insiders reported holding 914,527 shares in total, about $629.2K at the last price.
| Holder | Shares |
|---|---|
| Oliveto JosephPresident and CEO, Director | 446,244 |
| Muller LorenzChief Commercial Officer | 205,406 |
| Bharucha DavidChief Medical Officer | 113,181 |
| Hasija AmitCFO & EVP of Corp. Development | 99,848 |
| Nelson Jeffrey EdwardChief Operating Officer | 49,848 |
Questions about MIST
What does Milestone Pharmaceuticals Inc. do?
Milestone Pharmaceuticals Inc. is a company in the Health care sector, listed on NASDAQ as MIST. Its shares trade on NASDAQ under the ticker MIST.
What is Milestone Pharmaceuticals Inc.'s net worth?
Milestone Pharmaceuticals Inc. has a market value (market cap) of $85.7M at the latest share price, and shareholders' equity of $18.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Milestone Pharmaceuticals Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $84M.
When did Milestone Pharmaceuticals Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the stock exchange listing notice from October 28, 2026.
When is Milestone Pharmaceuticals Inc.'s next earnings report?
Milestone Pharmaceuticals Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare MIST with
Follow MIST
Get an email when Milestone Pharmaceuticals Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Milestone Pharmaceuticals Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.